Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Other Operating Expenses (2016 - 2025)

International Stem Cell (ISCO) has disclosed Other Operating Expenses for 16 consecutive years, with $2.2 million as the latest value for Q1 2025.

  • On a quarterly basis, Other Operating Expenses rose 76.66% to $2.2 million in Q1 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 55.84% decrease, with the full-year FY2023 number at $4.4 million, down 1.93% from a year prior.
  • Other Operating Expenses was $2.2 million for Q1 2025 at International Stem Cell, up from $1.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $2.2 million in Q1 2025 to a low of $962000.0 in Q1 2021.
  • A 5-year average of $1.2 million and a median of $1.1 million in 2021 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: fell 29.99% in 2021, then surged 76.66% in 2025.
  • International Stem Cell's Other Operating Expenses stood at $1.1 million in 2021, then skyrocketed by 30.87% to $1.4 million in 2022, then fell by 15.44% to $1.2 million in 2023, then grew by 7.02% to $1.3 million in 2024, then skyrocketed by 70.38% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ISCO's Other Operating Expenses are $2.2 million (Q1 2025), $1.3 million (Q3 2024), and $1.2 million (Q2 2024).